With #ADPD2026 drawing to a close, the discussions throughout the week have highlighted meaningful progress in treatments, diagnostics and prevention. We leave encouraged by the work shared in Copenhagen and the partnerships supporting progress across the dementia field.

In case you missed it at #ADPD2026: WDC member Phyllis Ferrell chaired the symposium “Blood Biomarkers: A Completed Chapter or Work in Progress? Practical Challenges and Solutions for Real‑World Implementation,” focused on advancing real‑world use of BBMs in Alzheimer’s disease.

In case you missed it at #ADPD2026: WDC trustee Philip Scheltens chaired the symposium “Insights Into the EVOKE and EVOKE+ Trials of Semaglutide in Early Alzheimer’s Disease,” opening the session and presenting new clinical and biomarker results.

In case you missed it, earlier today at #ADPD2026: Miia Kivipelto chaired the symposium “Continue Life Their Way: Early Intervention in Alzheimer’s Disease,” examining the value of early and continued management of early Alzheimer’s disease. WDC member Frank Jessen also presented during the session.

Following along from @leatgrinberg.bsky.social's #ADPD2026 plenary — a reminder that even as powerful new biomarkers emerge, studying brain tissue directly remains essential for grounding new discoveries in what the biology actually shows.

Day 1 #ADPD2026 is now under way. Earlier today Miia Kivipelto chaired “Prevention and Resilience in Dementia and Aging” symposium, where she also presented new findings from World‑Wide FINGERS. WDC Trustee, Philip Scheltens also presented on primary prevention of Alzheimer’s.

We’re glad to be in Copenhagen as #ADPD2026 begins. Our executive director, Lenny Shallcross, is attending, and we’re looking forward to new findings across treatments, diagnostics and prevention. Follow along this week as we highlight the work and presentations of our members and trustees.

Plasma biomarkers could transform Alzheimer's diagnosis — but only if health systems choose to adopt them. On 9 April, Dr Fiona Carragher chairs a WDC dialogue on moving biomarkers from research into real-world practice. Learn more: bit.ly/4diGBGM

Disease-modifying treatments for Alzheimer's are approved in Europe — but patients still can't access them. On 7 April, @hilaryevansnewton.bsky.social chairs a WDC discussion on advocacy, access, and what comes next. Learn more: bit.ly/4seP96q

The rise of “brain health” is opening doors with policymakers, but it also raises questions. This month’s WDC update in @alzdemjournals.bsky.social captures global perspectives on how the framing can reach new audiences while keeping the needs of dementia at the centre: bit.ly/40dSOVz

People aged 50–79 will soon outnumber children worldwide, concentrating much of the global risk of dementia. World Dementia Council executive director Lenny Shallcross looks at what an ageing population means for brain health 🧠, prevention and access to treatment: bit.ly/4ugCWiQ

📰 ICYMI: February’s @alzdemjournals.bsky.social features our 2026 programme — from brain health and advocacy to AI and technology, plus summits in Istanbul, London and Guangzhou — focused on moving dementia science into better care. Learn more: bit.ly/4qaA9EP

Registration is now open for the WDC Satellite Summit in Istanbul on 29 April 2026. Held the day before the @alzassociation.bsky.social AAIC Satellite Symposium, this invitation-only meeting will convene global leaders to advance brain health worldwide. Learn more: bit.ly/4o8Sd1j

📰 In the latest edition of @alzdemjournals.bsky.social, the World Dementia Council previews its 2026 programme: brain health and advocacy, AI and technology, and summits in Istanbul, London and Guangzhou to turn dementia science into better care. Read more: bit.ly/4qaA9EP

What role does advocacy play in shaping global dementia policy? Our next virtual dialogue — part of the WDC advocacy series — will tackle this question and more. 👉 Learn more: bit.ly/48JXQx4

The World Dementia Council is pleased to be a Brain Economy Action Forum Pathfinder organisation supporting “The Human Advantage: Stronger Brains in the Age of AI,” a new report from the McKinsey Health Institute and World Economic Forum. Learn more: bit.ly/4qrTUsh

Dementia is not just a medical challenge — it’s a global one. Ageing populations demand urgent action on research, care and innovation. The WDC is driving collaboration to keep dementia high on the global agenda. More: bit.ly/49ObAap

We were proud to attend the World Brain Health Forum 2026. Hosted by @institutducerveau.bsky.social it was an inspiring gathering of global leaders advancing brain health and dementia innovation. Collaboration is key to progress on diagnostics, treatments, and risk reduction.#WBHF2026

The World Dementia Council was proud to join this important conversation on advancing brain health and dementia research. Collaboration is key to driving progress and improving lives worldwide. #WBHF2026

🌍 The World Brain Health Forum 2026 continues today at the UNESCO House with its main conference, opened by Serge Weinberg, Jean Todt, Olivier Goy, Didier Samuel, and Stéphanie Debette, followed by inaugural speeches from Khaled El-Enany, H.E. Ban Ki-moon, and Dr. Tedros. #WBHF2026

Scientific progress in dementia is clear — but implementation is the next frontier. ICYMI: Our December update in Alzheimer’s & Dementia explores insights from the WDC session at the Cognitive Neurology Association Summit. Learn more: @alzdemjournals.bsky.social: bit.ly/3KULYQU

Where does the brain health narrative strengthen advocacy — and where does it risk becoming too broad? Our upcoming global dialogue brings leaders together to define sharper messaging and real-world application. Learn more: bit.ly/48JXQx4

Next year, WDC will host three Summits focused on advancing dementia progress — from public health implementation to clinical practice and strategic direction for the field. Explore the programmes: bit.ly/49exTYm

Wishing you a Happy New Year from the World Dementia Council! 🌍✨ We remain committed to turning breakthroughs into real-world impact — advancing diagnostics, treatments, and brain health for a brighter future. Here’s to progress in 2026.

As 2025 ends, we’re reflecting on a year of @WorldDementia updates published in @alzdemjournals.bsky.social. Each month, we shared insights from dialogues, summits and new series advancing dementia research, treatment, brain health and care. Highlights ⬇️

📢 WDC’s november @alzdemjournals.bsky.social update dives into the first session of our innovation dialogue series, focused on biomarkers and their promise for dementia care. Explore the discussion: bit.ly/3MBeuqX

🧠 Virtual dialogue on brain health advocacy — 27 Jan 2026. How is brain health framed as public policy? Where does the narrative work, and where does it need clarity as it overlaps with mental health, cognitive ageing and brain capital?🔗 Details: bit.ly/48JXQx4

WDC’s new dialogue series on innovation launched 31 Oct, with experts exploring breakthroughs in biomarkers and their potential to reshape dementia research, diagnosis and treatment. Read about it in the November edition of @alzdemjournals.bsky.social: bit.ly/3MBeuqX

It's a great day in San Diego for Day 2 of #CTAD2025! We look forward to sessions exploring the latest science. This afternoon, we will hold our working lunch on Driving Innovation where experts will discuss policy alignment with breakthroughs in biomarkers, AI, and precision medicine.

🔬 The World Dementia Council will host a working lunch at CTAD as part of our innovation project, exploring how collaboration and policy can accelerate progress in dementia treatment, diagnosis and prevention. Learn more: bit.ly/4npGD0Y

Earlier today WDC executive director, Lenny Shallcross had the honour of speaking at the Annual Summit of the Cognitive Neurology Association with our trustee Suvarna Alladi. Happening now our session with the @alzassociation.bsky.social.

Our Roundtable at the Cognitive Neurology Association Annual Summit is coming up this weekend. Together, we'll address the hard work of implementing dementia science in health systems: diagnosis, treatment and brain health. Learn more bit.ly/3Lw8ak4

In 2026 we’re hosting three Summits, each examining a different dimension of progress in dementia — from public health implementation, to strategic direction for the field, to clinical practice. Learn more about our Summit Programmes here: bit.ly/49exTYm

Later this week, we’re heading to the Annual Summit of the Cognitive Neurology Association. In partnership with @alzassociation.bsky.social, we’ll host a Workship on turning dementia science into real-world health system implementation. Learn more: bit.ly/3Lw8ak4

Ahead of our Roundtable at the Annual Summit of Cognitive Neurology Association next week, read the latest WDC Update in @alzdemjournals.bsky.social. It highlights our second global dialogue on dementia, with a focus on India’s leadership in brain health, prevention & treatment. Read: bit.ly/48RZ4I6

🧠 WDC Reminder: Our next virtual event “Lessons from innovators: biomarkers“ is tomorrow! We'll be discussing vital, collaborative work that is shaping the future of dementia research and care worldwide. This event is supported by @theaddf.bsky.social. Learn more: bit.ly/4kUT4Re

🧠 The World Dementia Council will host a lunch during the CTAD conference on 2 December. Chaired by Dr Joanne Pike, leaders will explore next-gen therapeutics, biomarkers, diagnostics, and digital health & AI—key themes shaping the future of dementia research. Learn more: bit.ly/4npGD0Y

🗞️ The October WDC Update is out in Alzheimer’s & Dementia! It features highlights from our second global meeting on dementia, with a focus on India’s leadership in research and care. Read more: bit.ly/48RZ4I6 via @alzdemjournals.bsky.social

Join us on 31 October for our next virtual event, “Lessons from innovators: biomarkers.” Chaired by two leading experts: Dr Howard Fillit & Dr Stacie Weninger, we’ll be discussing the latest innovations in the field. More info: bit.ly/4kUT4Re

🗓️ In case you missed it: At #AAIC25, the World Dementia Council and @alzassociation.bsky.social convened a powerful dialogue on advancing advocacy. The September @alzdemjournals.bsky.social issue reflects on the discussion: bit.ly/47PmkWJ

Revisiting our programme, “From Discovery to Delivery: Advancing Brain Health Worldwide” — an initiative focused on shaping public policy and bridging the gap between scientific breakthroughs and real-world delivery. Full overview: bit.ly/47UNxY8

The World Dementia Council is hosting a virtual event on “Lessons from innovators: biomarkers.” Supported by @theaddf.bsky.social, this dialogue will explore rapid advances & key challenges in developing new dementia diagnostics. More here: bit.ly/4kUT4Re

We are excited to announce our next WDC Satellite Summit will be held in Istanbul on 29 April 2026. In partnership with the @alzassociation.bsky.social, it will bring together global leaders together to drive progress in the region. Find out more: bit.ly/4o8Sd1j

That's a wrap on #35AEC! We enjoyed connecting with the community and our discussions on the future of dementia, from diagnostics and treatments to the evolution of advocacy. Thank you @alzheimereurope.bsky.social for hosting a wonderful gathering. While the conference has ended our work continues.

Read our daily #35AEC conference reports to catch up on what is happening at the 35th Alzheimer Europe Conference, taking place in Bologna, Italy. Yesterday was day two! Another fantastic day with a packed schedule... Read all about it: www.alzheimer-europe.org/news/second-...

When discussing the future of dementia advocacy we can't ignore brain health. “We must get to the point where people who are worried about their health associate what they eat, how they exercise & how they live as being connected to their brain health” WDC executive director Lenny Shallcross. #35AEC

Richard Angell notes: the original HIV advocates are no longer with us, but their legacy lives on. Their work shifted the focus of advocacy from a death sentence to prevention. Dr Pike reflects on similar progress with cervical cancer. Two important examples to learn from. #35AEC

Dr Joanne Pike highlights the uphill climb of getting new treatments to patients in part because the first disease-modifying Alzheimer's drug was approved via the FDA accelerated approval pathway. The experience showed the vital role of advocacy & public education for the next two approvals #35AEC

At #35AEC @richardangell.bsky.social from the Terence Higgins Trust made a powerful point in our session: "Not acting on Alzheimer’s is the ultimate economic" failure. The global cost of dementia is a clear call to action for governments to invest in diagnostics and treatments.

New diagnostics, treatments, and prevention interventions mark a decisive turning point for dementia. WDC Executive Director Lenny Shallcross is opening our session to discuss how advocacy must evolve as science advances. It's a key moment for our field. #35AEC